Trial reportDiabetes, obesity & metabolism2025
Efficacy and safety of once-weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT-2 trial.
Trial report in Diabetes, obesity & metabolism, 2025. The graph read 2 numbers from its abstract, feeding 1 cell of the map: it supports the treatment in 1. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
MATERIALS AND METHODS: This subpopulation analysis of 41 Japanese participants from three clinical trial sites in the SURMOUNT-2 trial evaluated the efficacy and safety of tirzepatide as an adjunct to lifestyle interventions in adults with body mass index ≥27 kg/m RESULTS: The mean percent change (standard error) in body weight from baseline to week 72 was statistically significantly greater for both tirzepatide 10 mg (p = 0.001) and 15 mg (p = 0.013) compared with placebo: -12.4% (1.8%) and -10.2% (1.8%), respectively, compared with -3.5% (1.8%).
MATERIALS AND METHODS: This subpopulation analysis of 41 Japanese participants from three clinical trial sites in the SURMOUNT-2 trial evaluated the efficacy and safety of tirzepatide as an adjunct to lifestyle interventions in adults with body mass index ≥27 kg/m RESULTS: The mean percent change (standard error) in body weight from baseline to week 72 was statistically significantly greater for both tirzepatide 10 mg (p = 0.001) and 15 mg (p = 0.013) compared with placebo: -12.4% (1.8%) and -10.2% (1.8%), respectively, compared with -3.5% (1.8%).
clause the extractor read what became the number
Where it lands on the map
Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.
What it adds to each cell
For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.
GIP/GLP-1 & amylin agonists×body weight & composition
SupportsOpen on the map →What to test next →28 readable studies in this cell: 27 favour the treatment, 1 find no difference, 0 favour the comparator.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial.Obesity (Silver Spring, Md.) · 2026Trial
- Efficacy and safety of once-weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT-2 trial.Diabetes, obesity & metabolism · 2025 · on this mapTrial
- Beyond Diabetes: The Vasculoprotective Effects and Anti-Atherosclerotic Potential of Tirzepatide.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The marked sentences are the ones the graph read a number from.
aimTo assess the efficacy and safety of once-weekly tirzepatide in Japanese participants with obesity and type 2 diabetes (T2D). MATERIALS AND
methodsThis subpopulation analysis of 41 Japanese participants from three clinical trial sites in the SURMOUNT-2 trial evaluated the efficacy and safety of tirzepatide as an adjunct to lifestyle interventions in adults with body mass index ≥27 kg/m
resultsThe mean percent change (standard error) in body weight from baseline to week 72 was statistically significantly greater for both tirzepatide 10 mg (p = 0.001) and 15 mg (p = 0.013) compared with placebo: -12.4% (1.8%) and -10.2% (1.8%), respectively, compared with -3.5% (1.8%). At week 72, 85.7% and 78.6% of participants in the tirzepatide 10 mg and 15 mg groups, respectively, had a body weight reduction of ≥5%, versus 46.2% of participants receiving placebo. Reductions in glycemic parameters, waist circumference and systolic blood pressure, as well as numerical improvements in the lipid profile, were also observed with tirzepatide. No new safety concerns were identified.
conclusionsIn Japanese adults with obesity and T2D, once-weekly treatment with tirzepatide (10 or 15 mg) demonstrated significant reductions in body weight compared with placebo, with the safety profile generally consistent with previous studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.